Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 9/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | GHSR | Q92847 | 2/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penetratin SCHEMBL29356568 | 0.97 | PTH1R (0.66) | PTH1RKEAP1IL23RRXFP1GHSR | |
| SCHEMBL29429587 | 0.95 | PTH1R (0.64) | PTH1RKEAP1IL23RRXFP1GHSR | |
| SCHEMBL29350300 | 0.95 | PTH1R (0.64) | PTH1RKEAP1IL23RRXFP1GHSR | |
| Penetratin SCHEMBL29450548 | 0.94 | KEAP1 (0.64) | PTH1RKEAP1IL23RRXFP1GHSR | |
| SCHEMBL30002139 | 0.94 | PTH1R (0.63) | PTH1RKEAP1IL23RRXFP1 | |
| SCHEMBL31749000 | 0.94 | PTH1R (0.63) | PTH1RKEAP1IL23RRXFP1GHSR | |
| SCHEMBL30299196 | 0.93 | PTH1R (0.67) | PTH1RKEAP1IL23RRXFP1GHSR | |
| Kqikiwfqnkkmkwkk-Nh2 SCHEMBL31748869 | 0.92 | PTH1R (0.60) | PTH1RKEAP1IL23RRXFP1GHSR | |
| SCHEMBL30617122 | 0.92 | PTH1R (0.61) | PTH1RKEAP1IL23RGHSRNPY2R | |
| SCHEMBL31232534 | 0.91 | PTH1R (0.68) | PTH1RKEAP1IL23RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3706801-B1 | PLATINUM COMPLEXES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12433893-B2 | Alpha polyglutamated pemetrexed and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-10 | — | — | US | disclosed |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | disclosed |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240252498-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2024-08-01 | — | — | US | disclosed |
| US-12048767-B2 | Gamma polyglutamated pralatrexate and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-12048766-B2 | Gamma polyglutamated tetrahydrofolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240024326-A1 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2024-01-25 | — | — | US | disclosed |
| US-11779584-B2 | Alpha polyglutamated pemetrexed and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11771700-B2 | Gamma polyglutamated lometrexol and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11730738-B2 | Alpha polyglutamated pralatrexate and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230000997-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | L.E.A.F. HOLDINGS GROUP LLC | 2023-01-05 | — | — | US | disclosed |
| EP-4010031-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | L.E.A.F Holdings Group LLC (US) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048767-B2 | Gamma polyglutamated pralatrexate and uses thereof | IFNG, GMFG, IL2 | PTH1R 1883/4885KEAP1 3423/4885IL23R 28/4885 |
| US-12048766-B2 | Gamma polyglutamated tetrahydrofolates and uses thereof | FPGS, DHFR, MTHFD1 | PTH1R 2764/4885KEAP1 2278/4885IL23R 414/4885 |
| US-12433893-B2 | Alpha polyglutamated pemetrexed and uses thereof | FPGS, PML, MTHFD1 | PTH1R 3052/4885KEAP1 3230/4885IL23R 872/4885 |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | PTH1R 4081/4885KEAP1 3080/4885IL23R 340/4885 |
| US-11779584-B2 | Alpha polyglutamated pemetrexed and uses thereof | FPGS, PML, MTHFD1 | PTH1R 3052/4885KEAP1 3230/4885IL23R 872/4885 |
| US-11771700-B2 | Gamma polyglutamated lometrexol and uses thereof | IFNG, GGCT, FPGS | PTH1R 3282/4885KEAP1 2491/4885IL23R 28/4885 |
| US-11730738-B2 | Alpha polyglutamated pralatrexate and uses thereof | IFNG, FPGS, PML | PTH1R 2340/4885KEAP1 3376/4885IL23R 118/4885 |
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | FOLH1, QPCT, SGTA | PTH1R 2730/4885KEAP1 2155/4885IL23R 386/4885 |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FOLR2, FOLR1, FPGS | PTH1R 2582/4885KEAP1 4011/4885IL23R 703/4885 |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | FPGS, GGCT, FOLR1 | PTH1R 4382/4885KEAP1 2513/4885IL23R 769/4885 |
| US-20230000997-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | FPGS, ALG1, PHOSPHO1 | PTH1R 4537/4885KEAP1 2954/4885IL23R 1019/4885 |
| US-20240252498-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | IFNG, GGCT, FPGS | PTH1R 3282/4885KEAP1 2491/4885IL23R 28/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | PTH1R 4382/4885KEAP1 2513/4885IL23R 769/4885 |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | IFNG, FPGS, MTX1 | PTH1R 2800/4885KEAP1 3056/4885IL23R 69/4885 |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | FPGS, PDF, STOML2 | PTH1R 2446/4885KEAP1 4512/4885IL23R 495/4885 |
| US-20240024326-A1 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | IFNG, FPGS, PML | PTH1R 2340/4885KEAP1 3376/4885IL23R 118/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | PTH1R 2708/4885KEAP1 4169/4885IL23R 32/4885 |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | QPCT, SGTA, IFNG | PTH1R 2414/4885KEAP1 2096/4885IL23R 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.